This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (27) Citing Articles via Google Scholar Google Scholar Articles by Afilalo, J. Articles by Eisenberg, M. J. Search for Related Content PubMed Articles by Afilalo, J. Articles by Eisenberg, M. J. Related Collections Related Articles

CLINICAL RESEARCH: LIPIDS AND ATHEROSCLEROSIS

Statins for Secondary Prevention in Elderly Patients

A Hierarchical Bayesian Meta-Analysis

Jonathan Afilalo, MD^_*, Gustavo Duque, MD, PhD^_*,, Russell Steele, PhD, J. Wouter Jukema, MD, PhD, Anton J.M. de Craen, PhD^|| and Mark J. Eisenberg, MD, MPH^_*,¶,1,_*

^_* Department of Medicine, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada
Division of Geriatrics and Bloomfield Center for Aging Research, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada
Department of Mathematics and Statistics, McGill University, Montreal, Canada
Division of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
^|| Division of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, Netherlands
^¶ Divisions of Cardiology and Clinical Epidemiology, Sir Mortimer B. Davis Jewish General Hospital, McGill University, Montreal, Canada.

Manuscript received April 9, 2007; revised manuscript received May 31, 2007, accepted June 25, 2007.

^_* Reprint requests and correspondence: Dr. Mark J. Eisenberg, 3755 Cote Ste Catherine, Suite A-118, Montreal, Quebec H3T 1E2, Canada. (Email: mark.eisenberg{at}mcgill.ca).

Objectives: This study was designed to determine whether statins reduce all-cause mortality in elderly patients with coronary heart disease.

Background: Statins continue to be underutilized in elderly patients because evidence has not consistently shown that they reduce mortality.

Methods: We searched 5 electronic databases, the Internet, and conference proceedings to identify relevant trials. In addition, we obtained unpublished data for the elderly patient subgroups from 4 trials and for the secondary prevention subgroup from the PROSPER (PROspective Study of Pravastatin in the Elderly at Risk) trial. Inclusion criteria were randomized allocation to statin or placebo, documented coronary heart disease, 50 elderly patients (defined as age 65 years), and 6 months of follow-up. Data were analyzed with hierarchical Bayesian modeling.

Results: We included 9 trials encompassing 19,569 patients with an age range of 65 to 82 years. Pooled rates of all-cause mortality were 15.6% with statins and 18.7% with placebo. We estimated a relative risk reduction of 22% over 5 years (relative risk [RR] 0.78; 95% credible interval [CI] 0.65 to 0.89). Furthermore, statins reduced coronary heart disease mortality by 30% (RR 0.70; 95% CI 0.53 to 0.83), nonfatal myocardial infarction by 26% (RR 0.74; 95% CI 0.60 to 0.89), need for revascularization by 30% (RR 0.70; 95% CI 0.53 to 0.83), and stroke by 25% (RR 0.75; 95% CI 0.56 to 0.94). The posterior median estimate of the number needed to treat to save 1 life was 28 (95% CI 15 to 56).

Conclusions: Statins reduce all-cause mortality in elderly patients and the magnitude of this effect is substantially larger than had been previously estimated.

Abbreviations and Acronyms   CHD = coronary heart disease   CI = credible interval   MI = myocardial infarction   QUOROM = Quality of Reporting of Meta-Analyses of Randomised Controlled Trials   RCT = randomized controlled trial   RR = relative risk

Related Articles

Prevention and Treatment: A Tale of Two Strategies

George A. Diamond and Sanjay Kaul
J. Am. Coll. Cardiol. 2008 51: 46-48. [Full Text] [PDF]

This article has been cited by other articles:

				L. Castilla-Guerra, M. del Carmen Fernandez-Moreno, M. D. Jimenez-Hernandez, and S. Chaturvedi EFFECT OF ATORVASTATIN IN ELDERLY PATIENTS WITH A RECENT STROKE OR TRANSIENT ISCHEMIC ATTACK Neurology, July 21, 2009; 73(3): 248 - 249. [Full Text] [PDF]

				R. Raine, W. Wong, G. Ambler, S. Hardoon, I. Petersen, R. Morris, M. Bartley, and D. Blane Sociodemographic variations in the contribution of secondary drug prevention to stroke survival at middle and older ages: cohort study BMJ, April 16, 2009; 338(apr16_2): b1279 - b1279. [Abstract] [Full Text] [PDF]

				K. P. Alexander, M. A. Blazing, R. S. Rosenson, E. Hazard, W. S. Aronow, S. C. Smith Jr, and E. M. Ohman Management of Hyperlipidemia in Older Adults Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2009; 14(1): 49 - 58. [Abstract] [PDF]

				A. N. DeMaria, O. Ben-Yehuda, J. J. Bax, G. K. Feld, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, S. M. Narayan, D. J. Sahn, et al. Highlights of the Year in JACC 2008. J. Am. Coll. Cardiol., January 27, 2009; 53(4): 373 - 398. [Full Text] [PDF]

				J W. Jukema and S. C Bergheanu Statins: established indications and controversial subgroups Heart, December 1, 2008; 94(12): 1656 - 1662. [Full Text] [PDF]

				B. Jacquemin, C. Antoniades, F. Nyberg, E. Plana, M. Muller, S. Greven, V. Salomaa, J. Sunyer, T. Bellander, A.-G. Chalamandaris, et al. Common Genetic Polymorphisms and Haplotypes of Fibrinogen Alpha, Beta, and Gamma Chains Affect Fibrinogen Levels and the Response to Proinflammatory Stimulation in Myocardial Infarction Survivors: The AIRGENE Study J. Am. Coll. Cardiol., September 9, 2008; 52(11): 941 - 952. [Abstract] [Full Text] [PDF]

				V. Bittner, D. Herrington, and N. Wenger Analyzing the Results of the Treating to New Targets Study Ann Intern Med, February 19, 2008; 148(4): 322 - 323. [Full Text] [PDF]

				G. A. Diamond and S. Kaul Prevention and treatment: a tale of two strategies. J. Am. Coll. Cardiol., January 1, 2008; 51(1): 46 - 48. [Full Text] [PDF]